Last reviewed · How we verify

Biodel — Portfolio Competitive Intelligence Brief

Biodel pipeline: 2 marketed, 0 filed, 4 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 4 Phase 3 2 Phase 2 4 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Humalog Mix 75/25 Humalog Mix 75/25 marketed Insulin combination product Insulin receptor Diabetes
recombinant human insulin recombinant human insulin marketed Insulin Insulin receptor Diabetes
Insulin VIAject™ (90%) Insulin VIAject™ (90%) phase 3 Rapid-acting insulin Insulin receptor Diabetes
Viaject 7 Viaject 7 phase 3 insulin analog insulin receptor Diabetes
VIAject™ VIAject™ phase 3 Rapid-acting insulin Insulin receptor Diabetes
Insulin VIAject™ (75%) Insulin VIAject™ (75%) phase 3 Rapid-acting insulin Insulin receptor Diabetes

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Eli Lilly and Company · 2 shared drug classes
  2. Novo Nordisk A/S · 2 shared drug classes
  3. Sanofi · 2 shared drug classes
  4. Institute for Clinical and Experimental Medicine · 1 shared drug class
  5. Informed Data Systems, Inc. · 1 shared drug class
  6. Kinderkrankenhaus auf der Bult · 1 shared drug class
  7. Mackay Memorial Hospital · 1 shared drug class
  8. Hospital Universitario Dr. Jose E. Gonzalez · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Biodel:

Cite this brief

Drug Landscape (2026). Biodel — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/biodel. Accessed 2026-05-13.

Related